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Abstract
Background: We have shown that pulmonary exposure to fine particulate matter (PM) impairs
endothelium dependent dilation in systemic arterioles. Ultrafine PM has been suggested to be
inherently more toxic by virtue of its increased surface area. The purpose of this study was to
determine if ultrafine PM (or nanoparticle) inhalation produces greater microvascular dysfunction
than fine PM. Rats were exposed to fine or ultrafine TiO2 aerosols (primary particle diameters of
~1 µm and ~21 nm, respectively) at concentrations which do not alter bronchoalveolar lavage
markers of pulmonary inflammation or lung damage.
Results: By histopathologic evaluation, no significant inflammatory changes were seen in the lung.
However, particle-containing macrophages were frequently seen in intimate contact with the
alveolar wall. The spinotrapezius muscle was prepared for in vivo microscopy 24 hours after
inhalation exposures. Intraluminal infusion of the Ca2+ ionophore A23187 was used to evaluate
endothelium-dependent arteriolar dilation. In control rats, A23187 infusion produced dose-
dependent arteriolar dilations. In rats exposed to fine TiO2, A23187 infusion elicited vasodilations
that were blunted in proportion to pulmonary particle deposition. In rats exposed to ultrafine
TiO2, A23187 infusion produced arteriolar constrictions or significantly impaired vasodilator
responses as compared to the responses observed in control rats or those exposed to a similar
pulmonary load of fine particles.
Conclusion: These observations suggest that at equivalent pulmonary loads, as compared to fine
TiO2, ultrafine TiO2 inhalation produces greater remote microvascular dysfunction.
Background
The association between cardiovascular disease and expo-
sure to airborne particulate matter (PM) is well estab-
lished. Nanotechnology is already well-integrated into
our daily lives, and appears to offer humankind novel
benefits limited only by our creativity. While the scope of
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these benefits is essentially unrestricted, benefits that are
specific to human health include: molecular imaging/
diagnosis, drug delivery, anticancer therapy and gene ther-
apy. However, if the unrestricted use of nanotechnology is
rushed to societal integration, and the health effects of
nanoparticles are not clearly identified, such technology
runs the risk of causing unanticipated adverse health
effects [1], and the true potential of the technology will
never be fully realized [2]. A fundamental first step in
avoiding these possible outcomes is the realization that
nanoparticles are not merely smaller variants of similarly
composed fine particles. This is evidenced by the observa-
tion that nanoparticles are primarily manufactured to pro-
duce specific differences in surface reactivity, solubility or
conductance.
Titanium dioxide ultrafine particles that fall within the
nanoparticle size range (one dimension less than 100
nm) are commonly used as photocatalysts to clean air and
water [3], as antibacterial agents on glass and steel [4], and
as components of many cosmetics and sunscreens. Once
in the lung, TiO2  nanoparticles initiate pulmonary
responses such as airway inflammation [5], alveolar mac-
rophage recruitment [6], and the activation of various
growth factors and chemokines [7]. Ultrafine particles
deposited in the lung may have the ability to translocate
to systemic sites within 24 hours of deposition [8-10].
Similarly, within 24 hours of deposition a substantial por-
tion of inhaled TiO2 nanoparticles escape phagocytosis
and enter the alveolar interstitium [11] and pulmonary
capillaries [12].
While the pulmonary responses to nano-sized titania par-
ticles appear to be well-understood, the systemic microv-
ascular effects of exposure to such particles are unknown.
We have previously shown that pulmonary exposure to
fine PM (PM2.5, particles with a mean aerodynamic diam-
eter of 0.1–2.5 µm) causes systemic microvascular dys-
function, most evident in the form of impaired or
abolished endothelium-dependent arteriolar dilation
[13,14]. These studies also provided evidence that this sys-
temic effect is not necessarily the result of the inherent
pulmonary toxicity of the particles, in that equivalent
doses of titanium dioxide (TiO2) and residual oil fly ash
caused similar, dose-dependent degrees of microvascular
dysfunction. While this indicates that larger TiO2 particles
elicit potent systemic microvascular effects, it cannot be
used to conclude that ultrafine TiO2 exposure will pro-
duce qualitatively or quantitatively similar biologic
effects.
Therefore, the purpose of this study was to characterize
systemic microvascular function after pulmonary expo-
sure (via inhalation) to fine or ultrafine TiO2 aerosols over
a range of concentrations, and determine if ultrafine TiO2
particles are inherently more toxic than larger, fine TiO2
particles.
Methods
Experimental Animals
Specific pathogen free male Sprague Dawley
[Hla:(SD)CVF] rats (6–7 wks old) were purchased from
Hilltop Laboratories (Scottdale, PA) and housed in an
AAALAC approved animal facility at the National Institute
for Occupational Safety and Health. Rats were housed in
laminar flow cages under controlled temperature and
humidity conditions and a 12 hr light/12 hr dark cycle.
Food and water were provided ad libitum. Rats were accli-
mated for 5 days before use and certified free of endog-
enous viral pathogens, parasites, mycoplasms,
Helicobacter and CAR bacillus. To ensure that all methods
were performed humanely and with regard for alleviation
of suffering, all experimental procedures were approved
by the Animal Care and Use Committees of the National
Institute for Occupational Safety and Health, and West
Virginia University.
Inhalation Exposure
An inhalation exposure system, containing a fluidized-
bed powder generator, an animal chamber, and several
aerosol monitoring devices, was developed for continu-
ous generation and monitoring of ultrafine or fine TiO2
aerosols for rodent exposure [15]. A schematic of the sys-
tem is presented in Figure 1. The system was designed
based on the criteria of simplicity, ability to disperse fine/
ultrafine TiO2 aerosols, and ease of maintenance. The
ultrafine and fine TiO2  powders were obtained from
DeGussa (Aeroxide TiO2, P25, primary particle size 21
nm, Parsippany, NJ) and Sigma-Aldrich (titanium (IV)
oxide, 224227, primary particle size 1 µm, St. Louis, MO),
respectively. To reduce the potential formation of agglom-
erates due to van der Waals force, the TiO2 powders were
carefully prepared for generation by sieving (to remove
the large agglomerates), drying (to avoid agglomerate for-
mation due to high humidity), and storage (to prevent
agglomerate attraction through contact charges). A fluid-
ized-bed aerosol generator was used in this study because
it was able to disperse powders effectively. A 19-liter
metabolism chamber that contains an animal cage was
modified for use as the whole-body exposure chamber.
The cage can accommodate 3 rats for each exposure. Dur-
ing exposure, TiO2mass concentrations were continuously
monitored with a Data RAM (DR-40000 Thermo Electron
Co, Franklin, MA) and gravimetrically measured with
Teflon filters. Aerosol concentrations between 1.5 and 20
mg/m3 were achieved by adjusting the powder feed rate in
the generator. Pulmonary deposition was estimated by the
formula: Pulmonary Load = aerosol concentration ×
minute ventilation × exposure duration × deposition frac-
tion, where minute ventilation and deposition fractionParticle and Fibre Toxicology 2008, 5:1 http://www.particleandfibretoxicology.com/content/5/1/1
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were estimated to be 200 cc and 10%, respectively. The
deposition fraction of 10% was based upon Kreyling's
alveolar deposition curve for inhaled ultrafine particles in
the rat [16]. The particle size distributions of TiO2 aerosols
were measured using a cascade impactor (MOUDI, MSP
Co., Shoreview, MN), an electrical mobility classifier
(SMPS, TSI Inc., Shoreview, MN), and an aerodynamic
sizing instrument (APS, TSI Inc.). The impactor was used
for measuring mass-based aerodynamic size distributions,
while the latter two sizing devices were combined for
determining number-based mobility size distributions. In
addition, temperature, relative humidity, and pressure in
the chamber were monitored throughout the exposure.
To verify that containment in the exposure chamber did
not cause an unintended biologic response, Sham/Con-
trol exposures (that matched the exposure duration of the
experimental groups) were performed throughout the
course of these experiments. Because no discernable sys-
temic or microvascular effect was observed in any condi-
tion, the data from these experiments were combined into
a single "Sham/Control" group. Furthermore, the sys-
temic and microvascular responses of this "Sham/Con-
trol" group were not different from those observed in
naive rats (data not shown).
Histopathology
At 24 hr post-exposure, lungs were rapidly removed and
inflated with 6 ml 10% neutral buffered formalin, rou-
tinely processed overnight in an automated tissue proces-
sor, embedded in paraffin, sectioned at 5 µm, and stained
with hematoxylin and eosin. The left lung lobe was evalu-
ated by a board-certified veterinary pathologist in a
blinded fashion.
Measurement of Pulmonary Particle Deposition
At 24 hr post-exposure, lungs were removed, weighed, fro-
zen at -80°C, and then lyophilized. After lyophilization,
the samples were prepared for analysis by inductively-
coupled plasma-atomic emission spectroscopy (ICP-AES)
[17]. Lung TiO2 burden was expressed as total lung bur-
den (µg).
Intravital Microscopy
The spinotrapezius muscle preparation has been used for
over 30 years as an experimental model to evaluate phys-
Schematic diagram of the TiO2 inhalation exposure system Figure 1
Schematic diagram of the TiO2 inhalation exposure system. Data-logging Real-time Aerosol Monitor (DataRAM). 
Aerodynamic Particle Sizer (APS). Scanning Mobility Particle Sizer (SMPS). Micro-Orifice Uniform Deposit Impactors 
(MOUDI).
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iological and pathophysiological phenomena at the
microvascular level [18,19]. The preparation has been an
essential tool in the fundamental understanding of: capil-
lary network development [20], neurogenic, humoral and
myogenic control of microvascular resistance [21-23] and
the physiological roles of O2, NO and Ca2+ in the micro-
circulation [24-26]. Furthermore, the spinotrapezius mus-
cle preparation has been continuously used to
characterize pathophysiological microvascular conse-
quences of chronic diseases such as diabetes [27], hyper-
tension [23,28,29], and heart failure [27]. Arterioles of the
first branching order were studied because these vessels, in
conjunction with their upstream feed arteries, account for
approximately 60% of total spinotrapezius muscle vascu-
lar resistance, and therefore, are of major importance for
local blood flow regulation [28].
At 24 hr post-exposure, rats were anesthetized with
sodium thiopental (Pentothal, 100 mg/kg, i.p.) and
placed on a heating pad to maintain a 37°C rectal temper-
ature. The trachea was intubated to ensure a patent airway,
and the right carotid artery was cannulated to measure
arterial pressure. The right spinotrapezius muscle was
then exteriorized for microscopic observation, leaving its
innervation and all feed vessels intact. After exterioriza-
tion, the muscle was gently secured over an optical pedes-
tal at its in situ length. The muscle was next enclosed in a
tissue bath for transillumination and observation.
Throughout the surgery and subsequent experimental
period, the muscle was continuously superfused with an
electrolyte solution (119 mM NaCl, 25 mM NaHCO3, 6
mM KCl and 3.6 mM CaCl2), warmed to 35°C, and equil-
ibrated with 95% N2 - 5% CO2 (pH = 7.35–7.40). Super-
fusate flow rate was maintained at 4–6 ml/min to
minimize equilibration with atmospheric oxygen [30].
The animal preparation was then transferred to the stage
of an intravital microscope coupled to a CCD video cam-
era. Observations were made with a 20X water immersion
objective (final video image magnification = 1460X).
Video images were displayed on a high-resolution color
video monitor and videotaped for off-line analysis. Dur-
ing videotape replay, arteriolar inner diameters were
measured with a video caliper (Cardiovascular Research
Institute, Texas A&M University).
Arteriolar endothelium-dependent dilation was evaluated
by assessing the capacity for Ca2+-dependent endothelial
NO formation in response to intraluminal infusion of the
calcium ionophore A23187 (Sigma). Glass micropipettes
were filled with a 10-7 M solution of A23187, inserted into
the arteriolar lumen, and A23187 was then infused
directly into the flow stream for 2-minute periods at ejec-
tion pressures of 5, 10, 20 and 40 psi. A 2-minute recovery
period followed each ejection. We have previously veri-
fied that this technique induces vasoactive responses that
are not the result of mechanical artifact [13,31]. At the end
of all intravital experiments, adenosine (ADO) was added
to the superfusate (10-4 M final concentration) to fully
dilate the microvascular network and determine the pas-
sive diameter of each arteriole studied.
Data and Statistical Analyses
Arteriolar diameter (D, µm) was sampled at 10-second
intervals during all control and infusion periods. Resting
vascular tone was calculated for each vessel as follows:
Tone = [(Dpass - Dc)/Dpass] × 100, where Dpass is passive
diameter under ADO and Dc is the diameter measured
during the control period (resting diameter). A tone of
100% represents complete vessel closure, whereas 0% rep-
resents the passive state. In order to evaluate arteriolar
responsiveness between individual groups with subtle dif-
ferences in resting diameter, arteriolar diameter was nor-
malized. In this case, arteriolar diameter was expressed as
a percentage of the maximum response and was calcu-
lated for each vessel as follows: Diameter (% of Maximum
Response) = [(DSS - Dc)/(Dpass- Dc)] × 100, where DSS is the
steady state diameter achieved during A23187 infusion.
All data are reported as means ± SE, where "n" represents
the number of arterioles evaluated and "N" represents the
number of rats studied. This distinction was made because
the experimental unit in the current study was the arteri-
ole. One to three microvessels were studied per rat. Given
the inherent microvascular heterogeneity in any given tis-
sue [32], judicious sampling of multiple vessels per rat
serves not only to properly represent such heterogeneity,
but also to ultimately reduce the number of animals
required to complete the data sets. Statistical analysis was
performed by commercially available software (Sigmastat,
Jandel Scientific). One-way repeated measures ANOVA
was used to determine the effect of a treatment within a
group, or differences among groups. Two-way repeated
measures ANOVA was used to determine the effects of
group, treatment and group-treatment interactions on
measured variables. For all ANOVA procedures, the Stu-
dent-Newman-Keuls method for post hoc analysis was
used to isolate pair wise differences among specific
groups. Significance was assessed at the 95% confidence
level (P < 0.05) for all tests.
Results
Table 1 lists the exposure parameters used for the current
inhalation exposures, as well as the calculated and actual
deposition values. The exposure parameters were used to
calculate pulmonary deposition (using aerosol concentra-
tion, minute ventilation, estimated deposition fraction,
and exposure duration). The actual pulmonary deposition
is used to identify experimental groups in subsequent
Tables and Figures. The primary count mode for the
ultrafine TiO2 aerosols was 100 nm, while it was 710 nmParticle and Fibre Toxicology 2008, 5:1 http://www.particleandfibretoxicology.com/content/5/1/1
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for the fine TiO2 aerosols (Figure 2). When considering
the whole size distribution, the former had a count geo-
metric mean diameter of 138 nm and a geometric stand-
ard deviation of 2.2, and the latter had a count geometric
mean diameter of 402 nm and a geometric standard devi-
ation of 2.4.
The exposures selected for this study were exposures
which do not alter bronchoalveolar lavage markers of pul-
monary inflammation or lung damage. Consistent with
the design, histopathology did not identify significant
inflammation in lung sections. The principal histopatho-
logic alterations in the lung consisted of particle accumu-
lation within alveolar macrophages, the presence of
anuclear macrophages, and an intimate association
between particle-laden alveolar macrophages and the
alveolar wall. Anuclear alveolar macrophages were not
observed in any of the 21 sham-exposed rats. Anuclear
alveolar macrophages were identified in 1 of 20 rats
exposed to ultrafine TiO2 (a rat in the 38 µg exposure
group), and in 16 of the 29 rats exposed to fine TiO2 (Fig-
ure 3A), including 1 of 6 rats in the 8 µg target exposure,
2 of 4 rats in the 20 µg target exposure, 5 of 6 rats in the
36 µg target exposure, 5 of 7 rats in the 67 µg target expo-
sure, and 3 of 6 rats in the 90 µg target exposure. Because
the macrophage cell membrane remains intact, anuclear
macrophages are presumed to represent an apoptotic
change.
In addition to the particle accumulation, macrophages
containing particles were frequently intimately associated
with the alveolar wall (Figures 3 and 4), a location, sug-
gestive of, but not diagnostic of, macrophage activation.
This change was difficult to quantify because it was
dependent upon identifying the macrophages which were
intimately associated with the alveolar wall. These macro-
phages were best demonstrated using cross-polarization
to demonstrate the titanium particles (Figures 3B and 4B).
Fine TiO2 particles were distinctly birefringent in cross-
polarized light and could be identified in both intracellu-
lar and extracellular locations, while ultrafine TiO2 parti-
cles were faintly birefringent in polarized light and were
only identified within macrophages (Figures 4B). Since
the size of ultrafine TiO2 particles should be below the size
visible in the light microscope, the observed ultrafine
TiO2 particles are presumed to represent agglomerates of
ultrafine particles. Consistent with the ultrafine particles
only being visible when agglomerated, ultrafine particles
were not observed in sham-exposed rats or rats receiving
the lowest exposure, but were seen in 1 of 4 rats at 6 µg tar-
get exposure, 1 of 4 rats at the 10 µg target exposure, 2 of
4 rats at the 19 µg target exposure, and all rats receiving
the 38 µg target exposure. Conversely, particles were seen
in the lungs of all rats exposed to fine TiO2 at any dose.
At the time of intravital experiments, rats in the 38 µg
ultrafine TiO2 group were slightly older than rats in all
other experimental groups (Table 2). Despite this subtle
age difference in one group, mean arterial pressure was
not different among all experimental groups. Resting
diameter, passive diameter and resting tone were not
Particle size distributions (Geometric Diameter, Dg) of  ultrafine TiO2 (A) and fine TiO2 (B) aerosols generated by the  inhalation exposure system Figure 2
Particle size distributions (Geometric Diameter, Dg) 
of ultrafine TiO2 (A) and fine TiO2 (B) aerosols gener-
ated by the inhalation exposure system. The ultrafine 
TiO2 aerosol has a primary mode at 100 nm and a secondary 
mode at 400 nm. The fine TiO2 aerosol has a primary mode 
at 710 nm and a secondary mode at 120 nm. These number-
based size distributions were determined by combining the 
data from SMPS and APS.
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Table 1: TiO2 aerosol profiles and group depositions.
Particle Type Aerosol Concentration (mg/m3) Exposure Time (min) Calculated Deposition (µg) Actual Deposition (µg)
Sham Control 0 240 0 0
Ultrafine 10 720 150 37.60 ± 1.90
Ultrafine 12 240 60 19.17 ± 0.36
Ultrafine 6 240 30 9.48 ± 0.32
Ultrafine 3 240 15 6.38 ± 0.13
Ultrafine 1.5 240 7 3.70 ± 0.08
Fine 15 480 150 89.80 ± 6.92
Fine 16 300 100 66.50 ± 3.82
Fine 12 240 60 36.33 ± 0.69
Fine 6 240 30 19.67 ± 1.07
Fine 3 240 15 8.26 ± 0.29
NOTE: Analysis of the filter samples collected from the exposure chamber do not indicate any detectable quantity of copper or tin (two major 
components of bronze beads used in the fluidized-bed generator). This indicates that the exposure environment does not have detectable levels of 
contaminants from the bronze beads used to disperse the bulk TiO2 samples.
Histopathologic alterations were subtle in the lungs of rats  inhaling fine TiO2 Figure 3
Histopathologic alterations were subtle in the lungs 
of rats inhaling fine TiO2. These changes principally con-
sisted of particle accumulation. Particles were difficult to see 
using transmitted light (A) but were birefringent when visual-
ized using cross-polarized light, enhancing their detection (B). 
The particle accumulation included apparently free TiO2 par-
ticles (open arrow), TiO2 particles within morphologically 
normal alveolar macrophages (dashed arrows), and TiO2 par-
ticles within macrophages without nuclei (anuclear macro-
phages, solid arrows). Both morphologically normal and 
anuclear macrophages were frequently in contact with the 
alveolar wall. H&E section. Reference bar = 20 µm.
A
B
Histopathologic alterations were particularly subtle in the  lungs of rats inhaling ultrafine TiO2 Figure 4
Histopathologic alterations were particularly subtle 
in the lungs of rats inhaling ultrafine TiO2. Ultrafine 
particle accumulation in alveolar macrophages (arrows) was 
difficult to see with transmitted light (A). Ultrafine particle 
accumulation within alveolar macrophages was more easily 
visualized as birefringent intracytoplasmic material using 
cross-polarized light (B). Macrophages containing ultrafine 
TiO2 particles were frequently in contact with the alveolar 
wall. H&E section. Reference bar = 20 µm.
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affected by aerosol dose, particle size or exposure method
(Table 3).
Consistent with our previous findings in rats exposed to
fine TiO2 via intratracheal instillation [13,14], inhalation
of fine TiO2 impaired arteriolar dilation in response to
A23187 infusion in a dose-dependent manner (Figure 5).
Although significantly compromised, arteriolar dilation
was still present after exposure to as much as 90 µg of fine
TiO2. The no-effect dose was determined to be 8 µg. At this
dose, arteriolar dilation at each ejection pressure was
identical to that observed in the sham-control group.
Inhalation of ultrafine TiO2 impaired arteriolar dilation in
response to A23187 infusion in a dose-dependent man-
ner (Figure 6). This was most evident at the 38 µg dose, in
which not only was dilation completely abolished, but
significant arteriolar constriction resulted during A23187
infusion. The no-effect dose was determined to be 4 µg, in
which arteriolar responsiveness was not different from
responses observed in sham-controls.
Because aerosol concentration and exposure time were
manipulated to obtain an array of pulmonary deposi-
tions, the possibility existed that such subtle manipula-
tions could themselves contribute to the resultant
microvascular dysfunction. To address this possibility,
additional exposures were performed in which exposure
time (2–8 hrs) and aerosol concentrations (3–12 mg/m3)
were manipulated to produce identical calculated pulmo-
nary depositions. Three groups of rats displayed identical
levels of microvascular dysfunction after exposure to 30
Table 2: Profiles of experimental animals used for intravital studies.
Exposure Parameters
TiO2 Dose/Group Aerosol Concentration (mg/m3) Duration (min) N Age (days) Weight (grams) Mean Arterial Pressure (mm 
Hg)
Sham Control 0 240 4 43 ± 1 206 ± 11 98 ± 9
38 µg Ultrafine 10 720 3 46 ± 3 * 228 ± 29 98 ± 6
19 µg Ultrafine 12 240 5 40 ± 1 188 ± 9 95 ± 4
10 µg Ultrafine 6 240 4 42 ± 1 224 ± 7 103 ± 2
10 µg Ultrafine 3 480 5 41 ± 1 202 ± 7 102 ± 10
10 µg Ultrafine 12 120 5 42 ± 1 217 ± 6 107 ± 7
6 µg Ultrafine 3 240 3 42 ± 1 216 ± 9 93 ± 7
4 µg Ultrafine 1.5 240 3 42 ± 1 207 ± 8 96 ± 7
90 µg Fine 15 480 4 42 ± 1 233 ± 4 97 ± 2
67 µg Fine 16 300 4 41 ± 1 214 ± 11 96 ± 3
36 µg Fine 12 240 4 41 ± 1 213 ± 6 100 ± 4
20 µg Fine 6 240 3 42 ± 1 209 ± 8 101 ± 3
8 µg Fine 3 240 5 42 ± 1 233 ± 9 106 ± 6
*, P < 0.05 vs. all other experimental groups.
Table 3: Resting variables for all arterioles studied in intravital studies.
Exposure Parameters
TiO2Dose/Group Aerosol Concentration 
(mg/m3)
Duration (min) n Resting Diameter 
(µm)
Passive Diameter 
(µm)
Resting Tone (% of 
maximum)
Sham Control 0 240 8 40 ± 2 99 ± 4 59 ± 3
38 µg Ultrafine 10 720 9 42 ± 2 106 ± 5 60 ± 3
19 µg Ultrafine 12 240 11 42 ± 1 100 ± 5 57 ± 3
10 µg Ultrafine 6 240 8 40 ± 2 98 ± 2 59 ± 3
10 µg Ultrafine 3 480 10 40 ± 2 95 ± 4 57 ± 3
10 µg Ultrafine 12 120 10 45 ± 2 99 ± 7 54 ± 3
6 µg Ultrafine 3 240 7 39 ± 1 105 ± 5 62 ± 2
4 µg Ultrafine 1.5 240 9 38 ± 1 97 ± 4 60 ± 2
90 µg Fine 15 480 8 45 ± 1 106 ± 5 57 ± 3
67 µg Fine 16 300 8 41 ± 1 105 ± 2 61 ± 2
36 µg Fine 12 240 8 39 ± 2 100 ± 7 60 ± 3
20 µg Fine 6 240 7 39 ± 1 92 ± 2 57 ± 2
8 µg Fine 3 240 12 41 ± 1 100 ± 5 58 ± 2Particle and Fibre Toxicology 2008, 5:1 http://www.particleandfibretoxicology.com/content/5/1/1
Page 8 of 12
(page number not for citation purposes)
µg ultrafine TiO2via different conditions (Figure 7). This
indicates that manipulation of exposure time or aerosol
concentration within the parameters used in the current
study neither attenuates nor augments the resultant
microvascular dysfunction (i.e., the response is dependent
on the time × concentration product of exposure).
Because actual pulmonary mass deposition was deter-
mined, three pair-wise comparisons of arteriolar respon-
siveness can be made between rats exposed to fine and
ultrafine TiO2 (Figure 8). At a deposition of 8–10 µg, fine
TiO2  produced no significant microvascular effects,
whereas ultrafine TiO2 significantly impaired arteriolar
dilations at 20 and 40 psi A23187 by 53% and 75%,
respectively (Top Panel). At a deposition of 19–20 µg, fine
TiO2 showed a trend towards an impaired dilation, while
ultrafine TiO2 produced arteriolar constrictions that were
significantly different from the responses in both the
sham-control and fine TiO2 groups (Middle Panel). At a
deposition of 36–38 µg, effects similar to the 19–20 µg
lung burden occurred but the intensity of arteriolar con-
striction after exposure to ultrafine TiO2 was more pro-
nounced (Bottom Panel). This suggests that at similar
pulmonary burdens, ultrafine particles produce greater
systemic microvascular dysfunction than fine particles.
Discussion
This is the first study to directly identify an impaired
vasodilator capacity in the systemic microcirculation after
nanoparticle inhalation. A second novel observation in
the current report is that for the same pulmonary mass
deposition, nanoparticles produce significantly greater
Manipulation of ultrafine TiO2 inhalation exposure time or  aerosol concentration does not alter the impairment of sys- temic arteriolar dilation Figure 7
Manipulation of ultrafine TiO2 inhalation exposure 
time or aerosol concentration does not alter the 
impairment of systemic arteriolar dilation. 2 hr@12 
mg/m3, n = 10; 4 hr@6 mg/m3, n = 8; 8 hr@3 mg/m3, n = 10. 
Values are means ± SE. *, P < 0.05 vs. Sham/Control group. 
Adenosine (ADO).
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Fine TiO2 inhalation impairs systemic arteriolar dilation 24  hours after exposure in a dose-dependent manner Figure 5
Fine TiO2 inhalation impairs systemic arteriolar dila-
tion 24 hours after exposure in a dose-dependent 
manner. Sham/Control, n = 8; 90 µg, n = 8; 67 µg, n = 8; 36 
µg, n = 8; 20 µg, n = 7; 8 µg, n = 12. Values are means ± SE. 
*, P < 0.05 vs. all groups. †, P < 0.05 vs. Sham/Control group. 
‡, P < 0.05 vs. 8–36 µg groups. Adenosine (ADO).
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Ultrafine TiO2 inhalation impairs systemic arteriolar dilation  24 hours after exposure in a dose-dependent manner Figure 6
Ultrafine TiO2 inhalation impairs systemic arteriolar 
dilation 24 hours after exposure in a dose-dependent 
manner. Sham/Control, n = 8; 38 µg, n = 9; 19 µg, n = 11; 
10 µg, n = 8; 6 µg, n = 7; 4 µg, n = 9. Values are means ± SE. 
*, P < 0.05 vs. 19 µg group. †, P < 0.05 vs. 10 µg group. ‡, P < 
0.05 vs. 6 µg group. Adenosine (ADO).
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systemic microvascular dysfunction than their larger, fine
counterparts of the same composition.
Nanoparticle inhalation attenuated systemic arteriolar
dilation in a dose-dependent manner (Figure 6). This was
most evident at a pulmonary deposition of 38 µg, in
which arterioles constricted in response to intraluminal
A23187 infusion. Arteriolar constriction during A23187
infusion is inconsistent with a healthy endothelium
because under these conditions A23187 normally inter-
acts only with endothelial cells to increase intracellular
Ca2+  concentration and subsequently stimulate nitric
oxide production [33]. Altered endothelial integrity and/
or permeability could allow luminal A23187 to interact
with smooth muscle cells, thereby increasing intracellular
Ca2+ concentration [34] and ultimately stimulate vaso-
constriction [35]. Alternatively, endothelial integrity may
be unaltered, but some aspect of particle exposure offsets
the prevailing balance of vasoconstrictors and vasodila-
tors. Indeed, A23187 has the potential to stimulate
endothelial production of vasoconstrictor prostanoids
[36,37]. Future studies must determine if endothelial
integrity has been compromised and/or the production of
vasoconstrictor prostanoids has been altered by nanopar-
ticle exposure. Of equal importance, future investigations
must characterize the ability of extrapulmonary nanopar-
ticles to alter the bioavailability of vasoactive metabolites.
The loss of microvascular vasodilator capacity can be a
profound influence on normal homeostasis in any organ.
In its most basic sense, this microvascular impairment
would decrease tissue perfusion, and therefore, compro-
mise function [38]. Our current techniques and findings
focus upon vasomotor function in single arterioles after
pulmonary nanoparticle exposure. To fully appreciate the
net effect of alterations in vascular regulation, total tissue
or organ blood flow must be studied. These approaches
can be challenging, and as such, other hemodynamic var-
iables that relate to tissue or organ blood flow can offer
considerable insight into the systemic microvascular con-
sequences that follow particle exposure. Mills et al. [39]
showed that diesel exhaust inhalation attenuates forearm
blood flow responsiveness to vasodilators. Further, pul-
monary exposure to diesel particles in the ultrafine range
potentiates myocardial ischemia in patients with pre-
existing coronary heart disease [40]. Urch et al. [41] have
reported acute increases in diastolic blood pressure within
2 hrs of particle exposure. Changes in diastolic blood pres-
sure are achieved primarily by alterations within the
resistance vasculature. Rundell et al. [42] reported a deficit
in hemoglobin reoxygenation following arterial occlu-
sion. Taken together, these findings are highly suggestive
of larger disturbances in microvascular blood flow regula-
tion after particle exposure.
Brook et al. [43] initially identified a subtle vasoconstric-
tion of the brachial artery in humans that inhaled fine par-
ticle matter. Recently, Rundell et al. [42] reported that this
conduit artery constricts similarly after ultrafine particle
inhalation. Because the smaller particles used by Rundell
et al. did not appear to be associated with a more robust
vasoconstriction in these studies (than those used by
Brook et al.), one might conclude that particle size does
not dictate resultant vascular dysfunction. However, it is
possible that this experimental model lacks sufficient sen-
sitivity to reveal such differences, or that fundamental dif-
ferences in particle composition, exposure protocols, and/
or experimental group profiles prevent a meaningful com-
parison between the two studies.
Systemic arteriolar dilation dose-response relationships at  various inhalation exposure burdens of ultrafine vs. fine TiO2 Figure 8
Systemic arteriolar dilation dose-response relation-
ships at various inhalation exposure burdens of 
ultrafine vs. fine TiO2. Open bars in all panels, Sham/Con-
trol group. Panel A, grey bars = 8 µg fine TiO2; black bars = 
10 µg ultrafine TiO2. Panel B, grey bars = 20 µg fine TiO2; 
black bars = 19 µg ultrafine TiO2. Panel C, grey bars = 36 µg 
fine TiO2; black bars = 38 µg ultrafine TiO2. *, P < 0.05 vs. 
Sham/Control and fine TiO2 at the same ejection pressure. 
Values are means ± SE.
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Ultrafine TiO2  has been shown to cause significantly
greater airway inflammation than fine TiO2 [5]. Based
upon the count geometric mean diameter (Figure 2),
nano-sized titania aerosols attenuate systemic endothe-
lium-dependent arteriolar dilation to a greater degree
than fine TiO2 aerosols (Figures 5, 6 and 8) at similar lung
burdens (Table 1). This observation is most evident at
lung burdens of 36 µg and 38 µg for fine and ultrafine par-
ticles, respectively. In this case, nano-sized titania aerosol
exposure was consistently associated with arteriolar con-
striction, whereas fine TiO2 inhalation was consistently
associated with an impaired arteriolar dilation (Figure 8,
bottom panel). This suggests that given the diverse nature
of particle size, shape and chemistry, the deposited parti-
cle mass may not be the ideal dose metric.
Data presented in the current study indicate that on an
equivalent mass basis, ultrafine TiO2 was approximately
one order of magnitude more potent than fine TiO2 in
causing systemic microvascular dysfunction. Oberdorster
[44] has proposed that particle surface area may be the
more appropriate dose metric for pulmonary effects of
ultrafine particles than mass. Therefore, we also analyzed
the results on an equivalent surface area of particles
deposited in the lungs. BET analysis, as described by Bru-
nauer, Emmett and Teller [45], was used to determine that
the surface area of ultrafine TiO2 was 48.08 m2/g while
fine TiO2 was 2.34 m2/g; i.e., ultrafine TiO2 had approxi-
mately 20 times more surface area per unit mass than fine
TiO2. Therefore, if one normalized the systemic microvas-
cular response to equivalent total particle surface area, the
fine TiO2 would be more potent than the ultrafine TiO2.
This conclusion is likely the result of an over estimation of
the total ultrafine surface area delivered to the lungs since
the BET method measures the gas absorptive surface area
of the primary particles, rather than the actual physical
surface of the aerosolized agglomerates. Indeed, Shvedova
et al. [46] reported that the pulmonary response to
ultrafine carbon black was significantly increased upon
improved nanoparticle dispersion.
It is important to note that actual pulmonary particle dep-
osition was significantly less than the calculated deposi-
tion (Table 1). This may be due to a number of reasons.
First, it is very likely that particle clearance occurs in the 24
hrs after exposure, and particularly during the 720 minute
exposures that took place over three days. Second, biolog-
ical heterogeneity among rats may contribute to differ-
ences in the calculated vs. the actual particle depositions.
In this case, subtle differences in minute volumes or dep-
osition fractions among rats could contribute to the diver-
gent measurements. However, despite manipulation of
aerosol concentration (3–12 mg/m3) or exposure time
(2–8 hrs), the intensity of microvascular dysfunction was
not different among these groups 24 hrs after exposure
(Figure 7). This suggests that the ranges of variables used
to obtain our target pulmonary loads are not responsible
for observed biologic effects in either the lung or the sys-
temic microcirculation.
The opportunity to directly compare the microvascular
responses to two different exposure methods presented
itself in this study. When arteriolar responses between rats
exposed to similar doses of fine TiO2 (90 µg via inhalation
vs. 100 µg via intratracheal instillation [14]) are com-
pared, no significant differences are apparent in the result-
ant microvascular dysfunction (data not shown). This
suggests that the method of particle introduction to the
lungs does not artificially induce systemic microvascular
dysfunction.
The physiological relevance of intratracheal instillation is
frequently questioned. Intratracheal instillation is a com-
monly used exposure method because it is rapid, econom-
ical and consistent across multiple animals. Further,
intratracheal instillation can produce a relatively uniform
pulmonary particle distribution if exposure doses are kept
low [47]. However, in regards to the true in vivo environ-
ment, intratracheal instillation bypasses many important
physiological processes. Hence, the "gold standard" of
particle exposure remains via inhalation.
Conclusion
In the time since we first reported that systemic microvas-
cular dysfunction follows PM exposure [13], nanotech-
nology products have become considerably imbedded in
most every aspect of daily life. It is also clearly apparent
now that the benefits of nanotechnology are far reaching.
Unfortunately, not only are the precise mechanisms
through which inhaled particles exert systemic biologic
effects unknown, but also the scope of biologic targets
and/or end points is greater when nanoparticles are con-
sidered. By definition, this later observation may be due
largely because of particle size, but surface chemistry of
nanoparticles must also be taken into account in future
studies. The ultrafine particles used in the current study
represent manufactured particles in the "nano" size range,
and after pulmonary deposition, they exerted a robust
biologic effect. It is unclear at this time what the most
appropriate dose metric is for nanoparticles, but it is
apparent from our studies and many others that mass
does not consistently appear to be the ideal metric. Inde-
pendent of the appropriate dose metric is our consistent
observation that pulmonary particle exposure initiates
systemic microvascular dysfunction, and this observation
is now extended to nanoparticles.
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